Molecular Templates (MTEM) Competitors

Cogent Biosciences (NASDAQ:COGT) and Molecular Templates (NASDAQ:MTEM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, community ranking, valuation and institutional ownership.

Is COGT or MTEM more profitable?

Cogent Biosciences has a net margin of 0.00% compared to Molecular Templates' net margin of -61.35%. Cogent Biosciences' return on equity of -112.55% beat Molecular Templates' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-112.55%	-60.44%
Molecular Templates	-61.35%	-260.50%	-46.90%

Which has better valuation & earnings, COGT or MTEM?

Molecular Templates has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Molecular Templates, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$192.41M	-$2.48	-3.71
Molecular Templates	$57.31M	0.04	-$8.12M	-$2.70	-0.14

Does the MarketBeat Community believe in COGT or MTEM?

Molecular Templates received 57 more outperform votes than Cogent Biosciences when rated by MarketBeat users. However, 70.72% of users gave Cogent Biosciences an outperform vote while only 67.32% of users gave Molecular Templates an outperform vote.

Company	Underperform	Outperform
Cogent Biosciences	Outperform Votes 285 70.72%	Underperform Votes 118 29.28%
Molecular Templates	Outperform Votes 342 67.32%	Underperform Votes 166 32.68%

Which has more risk and volatility, COGT or MTEM?

Cogent Biosciences has a beta of 1.72, meaning that its stock price is 72% more volatile than the S&P 500. Comparatively, Molecular Templates has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500.

Does the media refer more to COGT or MTEM?

In the previous week, Cogent Biosciences had 18 more articles in the media than Molecular Templates. MarketBeat recorded 20 mentions for Cogent Biosciences and 2 mentions for Molecular Templates. Cogent Biosciences' average media sentiment score of 0.34 beat Molecular Templates' score of -0.08 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Molecular Templates	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders & institutionals believe in COGT or MTEM?

95.5% of Molecular Templates shares are owned by institutional investors. 5.9% of Cogent Biosciences shares are owned by insiders. Comparatively, 13.9% of Molecular Templates shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Do analysts recommend COGT or MTEM?

Cogent Biosciences currently has a consensus price target of $14.83, suggesting a potential upside of 61.41%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cogent Biosciences is more favorable than Molecular Templates.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Molecular Templates	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Cogent Biosciences beats Molecular Templates on 10 of the 17 factors compared between the two stocks.